Avalon GloboCare Corp. announced that the Company has signed a memorandum of understanding with Lu Daopei Hematology Institute to co-develop precision companion diagnostics (CDx) for chimeric antigen receptor (CAR)-T cell therapies. To further strengthen its CDx development capabilities, Avalon has appointed Dr. Hongxing Liu, M.D., M.S., Executive President of LDHI and a world-renowned expert in precision diagnostics for hematologic malignancies, to its Scientific and Clinical Advisory Board.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.439 USD | +4.52% |
|
-6.64% | -9.11% |
1st Jan change | Capi. | |
---|---|---|
-9.11% | 4.87M | |
-15.37% | 8.55B | |
+64.74% | 4.23B | |
+4.36% | 2.68B | |
-2.80% | 2.61B | |
-54.53% | 1.82B | |
-19.59% | 1.66B | |
-21.51% | 1.42B | |
+15.98% | 1.19B | |
-48.13% | 1.05B |
- Stock Market
- Equities
- ALBT Stock
- News Avalon GloboCare Corp.
- Avalon GloboCare Corp. Appoints Hongxing Liu to Scientific and Clinical Advisory Board